Biofield Corporation in a medical technology company that has developed an innovative system for detecting breast cancer through the skin in a non-invasive and objective procedure. Biofield Corporation is in the business of bringing advanced medical technologies and solutions to the global marketplace. Possessing a number of well-developed proprietary technologies, Biofield is in a position to become the premier global provider of non-invasive diagnostic medical devices, most currently in the field of breast cancer screening and diagnosis. These unique technologies have enormous potential applications for the healthcare industry worldwide, allowing Biofield to project rapid growth and global recognition.

Over $70 million invested in proprietary technology
- Extensive patent protection
- Product development completed
- Clinical testing completed
- Research Phase: 463 patients (CE Mark)
- Pivotal Trials: 1835 total split into training and test
- Outcome Studies: 389 patients (Post Market Studies)

Regulatory:
- CE Mark Certification completed
- Low-cost manufacturing in place
- Attractive to all major markets worldwide
- Inexpensive to purchase, train and use
- Predictable revenue stream
- Single-use disposable sensors
- Attractive margins on device and sensors
- Additional revenue stream through processing of diagnostic results
-Inexpensive for patients and profitable to provider
- Tests are priced at or below mammogram screenings